

Ifa

PATENT APPLICATION

File No: 03-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Wenfeng Xu, Wayne Kindsvogel, Yasmin A. Chandrasekher, Stacey

R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V.

Sivakumar, Margaret D. Moore

Serial No. : 10

10/807,837

Group Art Unit

1646

Examiner

: March 24, 2004

Filed For

: ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND

METHODS OF USING IN INFLAMMATION

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence, comprising:

- 1. Information Disclosure Statement
- 2. PTO-1449 Form
- 3. 51 References
- 4. Return Postcard

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on April 7, 2005.

Kim M. Goplen



PATENT APPLICATION

File No: 03-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Wenfeng Xu, Wayne Kindsvogel, Yasmin A. Chandrasekher, Stacey

R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V.

Sivakumar, Margaret D. Moore

Serial No. : 10/807,837

Group Art Unit : 1646

Examiner

Filed : March 24, 2004

For : ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND

METHODS OF USING IN INFLAMMATION

Date Submitted : April 7, 2005

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the examination of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

In accordance with 37 C.F.R. 1.97, the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been conducted, nor shall it be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. Applicants believe that their invention as claimed is patentable over the references. It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event that a fee is due, please charge any fee or credit any overpayment to Deposit Account No. 26-0290.

Respectfully submitted,

Shelby J. Walker Registration No. 45,192

FORM PT (REV 2-32)			ARTMENT	File No. 03-02		Serial No. 10/807,837			
/0	(3)	DISCLOSURE Jse several shee		INT BY APPLICANT ary)	Applicant(Wenfeng				
.n 11 W 2					Filing Date: Grou March 24, 2004		Group: 1646		
EXAMINER	EPH		τ	J.S. PATENT DOCUME					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	A1	5,488,032	01/30/96	Dower et al.	514	2			
	A2	5,965,704	10/12/99	Lok et al.	530	350			
	A3	6,274,710	08/14/01	Dumoutier et al.	530	387.9			
		•	FOI	REIGN PATENT DOCUM	MENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	A4	1191035	03/27/02	Europe					
	A5	WO01/40467	06/07/01	WIPO					
	A6	WO98/37193	08/27/98	WIPO					
	A7	WO01/36467	05/25/01	WIPO					
	A8	WO02/066647	08/29/02	WIPO					
	A9	WO02/024912	03/28/02	WIPO					
	A10	WO98/02542	01/22/98	WIPO			<u> </u>		
	•	OTHER DOC	UMENTS (Including Author, Title,	Date, Pertine	ent Patents,	etc.)		
	All			Cutting Edge: STAT Activation E Types," J. Immunol. 167:3545-3		nd mda-7 Thro	ough IL-20 Receptor		
	A12		Dumoutier, L et al.,"Cloning and Characterization of IL-22 Binding Protein, a Natural Antagonist of IL-10-Related T Cell-Derived Inducible Factor/IL-22," <i>J. Immunol.</i> 166:7090-7095, 2001.						
*	Al3	Koter and N	nko et al., "Ide	ntification, Cloning, and Charact Activity," <i>J. Immunol.</i> 166:7096	erization of a No	ovel Soluble Ro	eceptor That Binds IL-22		
		andi	reationizes its	ixeavity, 3. inimunot. 100.7070	7013, 2001.				
	A14		Xu et al., "A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist," <i>Proc. Nat. Acad. Sci.</i> 98:9511-9516, 2001.						
		1 1	Gruenberg et al., "A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta," <i>Genes and Immunity</i> 2:329-334, 2001.						
	A15				e human IL-10 r	eceptor with pr	ererential expression in		
	A15	place Xie e	nta," <i>Genes ar</i> t al., "Interleu	ad Immunity 2:329-334, 2001. kin (IL)-22, a Novel Human Cyto	okine That Signa	ls through the			
		place Xie e	nta," <i>Genes ar</i> t al., "Interleu	ad Immunity 2:329-334, 2001.	okine That Signa	ls through the			
		Xie e Prote	t al., "Interleu ins CRF2-4 ar outier et al., "O l Cytokine Str	ad Immunity 2:329-334, 2001. kin (IL)-22, a Novel Human Cyto	okine That Signa 0):31335-31339 L-10-Related T	ds through the , 2000.	Interferon Receptor-related anducible Factor (IL-TIF), a		
Examiner	Al6	Xie e Prote	t al., "Interleu ins CRF2-4 ar outier et al., "O l Cytokine Str	kin (IL)-22, a Novel Human Cytod IL-22R," <i>J. Biol. Chem.</i> 275(4)	okine That Signa 0):31335-31339 L-10-Related Toducible by IL-9,	ds through the , 2000.	Interferon Receptor-related anducible Factor (IL-TIF), a		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		File No. 03-02		Serial No. 10/807,837			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						Applicant(s): Wenfeng Xu et al.			
						e: 2004	Group: 1646		
				U.S. PATENT DOCUMEN	ITS				
EXAMINER INITIAL			DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
			FO:	LREIGN PATENT DOCUM	IENTS				
Examiner Initial			DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	A18	WO99/07848	02/18/99	WIPO					
	A19	WO00/73457	12/07/00	WIPO					
	A20	WO00/77037	12/21/00	WIPO					
	A21	WO00/24758	05/04/00	WIPO					
	A22	WO00/39161	07/06/00	WIPO					
	A23	WO00/65027	11/02/00	WIPO					
	A24	WO00/70049	11/23/00	WIPO					
	A25	WO01/16318	03/08/01	WIPO					
	A26	WO01/46422	06/28/01	WIPO					
	A27	WO01/98342	12/27/01	WIPO					
	A28	WO02/20569	03/14/02	WIPO					
 	A29 A30	WO02/072607 WO03/035096	09/1902	WIPO			-		
7	1 A30		05/01/03 CUMENTS	WIPO (Including Author, Title, I	l Date. Pertine	nt Patents.	etc.)		
···	1 101					•	·		
` •	A31	Dumoutier et al. "Human interleukin-10-related T cell-derived inducible factor: Molecular cloning and functional characterization as an hepatocyte-stimulating factor," <i>Proc. Nat. Acad. Sci. 97(18)</i> :10144-10149, 2000.							
	A32	1 .	Dumoutier et al., IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes," Genes and Immunity. 1:488-494, 2000.						
	A33	Xn	Xu, X. et al., EMBL Database, Chinese National Human Genome Center at Shanghai, 5 Oct. 2000:						
		1 1	AV714177.						
	A34	Incy	Incyte Pharmaceuticals, Inc. clone, 1999: SHLW01158999.						
	A35	Well	Wells, "Additivity of Mutational Effects In Proteins," <i>Biochemistry</i> 29(37):8509-8517, 1990.						
	A36		Liu et al., "Expression Cloning and Characterization of a Human IL-10 Receptor," <i>J. Immunol.</i> 152:1821-1829, 1994.						
	A37		Blumberg et al., "Interleukin 20: Discovery, Receptor Identification, and Role in Epidermal Function," Cell						
		<u> 104:</u>	9-19, 2001.		·				
Examiner				Date consid	dered				
				whether or not citation is in ot considered. Include copy					

				MENT OF COMMERCE TRADEMARK OFFICE	File No. 03-02 Serial No. 10/807,837						
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)					Applicant(s): Wenfeng Xu et al.						
(Ose several sheets if necessary)						Filing Date: Group: 1646 March 24, 2004					
			Ţ	U.S. PATENT DOCUMENT	rs	•					
EXAMINER DOCUMENT NUMBER DATE NAM				Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
	<u> </u>		FOI	REIGN PATENT DOCUM	ENTS	L .					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
	<u>I</u>	OTHER DOC	CUMENTS (Including Author, Title, D	ate, Pertine	nt Patents, o	etc.)				
	A38 Zhang et al., "Identification, Purification, and Characterization of a Soluble Interleukin (IL)-13-binding Protein," J. Biochem. 272:9474-9480, 1997.										
	A39		Kotenko et al., "Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes," <i>Oncogene 19</i> :2557-2565, 2000.								
₹	A40		Kotenko et al., "Identification of the Functional Interleukin-22 (IL-22) Receptor Complex," <i>J. Biochem.</i> 276(4):2725-2732, 2001.								
	A41		Wei et al., "Cloning and characterization of mouse IL-22 binding protein," Genes and Immunity 34:204-211, 2003.								
	A42	Bork	Bork et al., "Go hunting in sequence databases but watch out for the traps," TIG 12(10):425-0426, 1996.								
	A43	Bork	Bork, "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," Genome Research 10:398-400, 2000.								
	A44		Sempowski et al., "Subsets of Murine Lung Fibroblasts Express Membrane-Bound and Soluble IL-4 Receptors," J. Immonol. 152: 3606-3614, 1994.								
	A45		Bork et al., "Predicting functions from protein sequences – where are the bottlenecks," <i>Nature Genetics</i> 18:313-318, 1998.								
	A46		Parrish-Novak et al., "Interleukins 19, 20, and 24 Signal through Two Distinct Receptor Complexes," J. Biochem 277(49):47517-47523, 2002.								
	A47		Uhlar et al., "Serum amyloid A, the major vertebrate acute-phase reactant," Eur. J. Biochem. 265:501-523, 1999.								
Examiner	<u> </u>	11		Date consid	ered						
				whether or not citation is in cot considered. Include copy							

		_	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			03-02	Serial No. 10/807,837		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)					1	Applicant(s): Wenfeng Xu et al.			
	(Ose several sheets if necessary)					Filing Date: Grou March 24, 2004			
		,		U.S. PATENT DOCUMEN	NTS				
Examiner Initial		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
		<u> </u>	FC	OREIGN PATENT DOCUM	MENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
P	A48 A49 A50 A51	Hilli Hilli Hilli	ier et al., Gen ier et al., Gen ier et al., Gen	S (Including Author, Title, Bank Accession No. AA132964, 1988) Bank Accession No. T70354, 1995 Bank Accession No. T70439, 1995 BL Database, AC007458, 1999.	995.	ent Patents,	etc.)		
Examiner				Date cons	idered				
				l, whether or not citation is in not considered. Include cop			·		